Sanofi·Healthcare / Pharmaceuticals·Paris, France·Founded 2004·Last verified 31 May 2026
50
out of 100
Making progressPending ReviewMixed evidence· 14 src

Sanofi has delivered genuine absolute emission reductions (47% Scope 1&2, 10% Scope 3 vs 2019) and SBTi-validated net-zero targets to 2045. Weaknesses: Scope 3 progress lags operations; biodiversity gains are not yet net-positive; recurring pollution incidents at Mourenx plant; misaligned trade association memberships undermine climate credibility.

The calculation

Every score shows its working.

Same formula for every company. No curve. No private weighting.

SINK = (0.3 × Base + 0.7 × Performance) × Scale
Industry base impact
Healthcare / Pharmaceuticals sector ceiling.
45 / 100
Performance score
Sum of the 10 rubric questions, scored 0–10 each.
68 / 100
Raw score
Weighted average before scale penalty.
(0.3 × 45) + (0.7 × 68) = 61.1
Scale penalty
Multiplier based on absolute emissions volume — physics-first.
× 0.82
Final score
Rounded. Making progress.
50 / 100
The ten questions

Where Sanofi is strong, and where it isn't.

Strongest on Carbon Footprint — Operations and Targets & Commitments (8/10, 8/10). Weakest on Controversies & Red Flags and Water Impact (6/10, 6/10).

Where the evidence comes from

Every document used, listed.

14 sources used in this assessment. All publicly available. Each row shows which rubric questions it informed.

[1]Self-reported
Sanofi Sustainability Statement 2024 (CSRD-aligned)
2025
Q1Q2Q3Q4Q6Q7Q8Q9
View →
[2]Self-reported
Sanofi Climate & ESG Index
Ongoing
Q1Q2Q3Q4Q8
View →
[3]Third-party verified
DitchCarbon — Sanofi Emissions Profile
Ongoing
Q1Q2Q3
View →
[4]Self-reported
Building the Road to Zero — Sanofi Climate Roadmap
Unknown
Q3
View →
[5]Self-reported
Sanofi Energy & Renewable Strategy
Ongoing
Q4
View →
[6]Self-reported
Sanofi Biodiversity & Nature Impact
Ongoing
Q5
View →
[7]Third-party verified
World Benchmarking Alliance — Nature Benchmark (Pharma Sector)
Ongoing
Q5Q7
View →
[8]Self-reported
Sanofi Circular Economy & Waste Management 2025
2025
Q6
View →
[9]Self-reported
Sanofi Eco-Design & Resource Use
Ongoing
Q6
View →
[10]Self-reported
Sanofi Water Stewardship
Ongoing
Q7
View →
[11]Self-reported
Sanofi Investor Relations — ESG & Governance
Ongoing
Q9
View →
[12]Third-party verified
Net Zero Tracker — Sanofi Commitments
Ongoing
Q8
View →
[13]Third-party verified
InfluenceMap — Sanofi Climate Policy Alignment
Ongoing
Q10
View →
[14]Public record
FiercePharma — Sanofi Mourenx Plant Neurotoxin Leak (2023)
2023
Q10
View →

If you believe a source has been misread or a newer version exists, submit a challenge.

Sanofi in context

Where Sanofi sits among healthcare / pharmaceuticals peers.

Among the 11 major healthcare / pharmaceuticals brands we've scored, Sanofi is tied =2nd of 11, with 2 others.

=2/11
Sanofi's rank
46
Industry average
39
Industry low
52
Industry high
How this score has moved

Sanofi's score over time.

today

Score history begins 4 April 2026.

As Sanofi's score updates, the trajectory will appear here.

We're backfilling historical scores for FTSE 100 and S&P 100 companies over the coming weeks.

What's being contested

This score is not currently being contested.

Every challenge is published. We'd rather be corrected than wrong — that's the whole point.

No challenges submitted yet. If you have evidence that contradicts this score, you can challenge any question above — cite a public source and we'll review it.

About Sanofi

Sanofi is a multinational pharmaceutical company headquartered in Paris, France, with 106,566 employees and €41.1B annual revenue (FY2024). It manufactures prescription drugs, vaccines, and specialty care products across oncology, immunology, and rare diseases, ranking among Europe's largest pharma players.

Founded
2004
Headquarters
Paris, France
Employees
~90,000
Annual revenue
€43.1B (FY2023)
Company website ↗
Track Sanofi

We'll let you know when the score moves.

Email alerts when a rubric question is verified, a challenge is resolved, or the overall score changes.

THE SUNDAY RUNDOWN

Which companies moved this week, and why.

One email, every Sunday. Score changes, new research, the stories behind the numbers. Free.

No spam. Unsubscribe in one click.

HOW SINK STAYS INDEPENDENT

Readers and institutions support our work. Companies can pay to submit evidence we couldn't find. Neither type of payment changes a score.